The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study

被引：0
作者：
Shao, Z. [1 ]
Huang, T. [2 ]
Fan, Z. [3 ]
Wang, Y. [4 ]
Yan, X. [5 ]
Yang, H. [6 ]
Wang, S. [7 ]
Pang, D. [8 ]
Li, H. [9 ]
Wang, H. [10 ]
Geng, C. [11 ]
Huang, L. [12 ]
Siddiqui, A. [13 ]
Wang, B. [14 ]
Xie, B. [15 ]
Sun, G. [16 ]
Restuccia, E. [17 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Breast Canc, Shanghai, Peoples R China
[2] Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China
[3] Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[4] Shandong Canc Hosp, Breast Canc Ctr, Jinan, Peoples R China
[5] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[6] Zhejiang Canc Hosp, Breast Surg, Hangzhou, Peoples R China
[7] Peking Univ Peoples Hosp, Breast Ctr, Beijing, Peoples R China
[8] Harbin Med Univ, Dept Breast Surg, Harbin, Peoples R China
[9] Beijing Canc Hosp, Breast Canc Ctr, Beijing, Peoples R China
[10] Affiliated Hosp Qingdao Univ, Dept Breast Ctr, Qingdao, Peoples R China
[11] Fourth Hosp Hebei Med Univ, Breast Ctr, Shijiazhuang, Hebei, Peoples R China
[12] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[13] Roche Prod Ltd, Prod Dev Clin Oncol, Welwyn Garden City, Herts, England
[14] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[15] Roche China Holding Co Ltd, Biostat, Shanghai, Peoples R China
[16] Roche China Holding Co Ltd, PD China, Shanghai, Peoples R China
[17] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1MO
引用
收藏
页码：S1431 / S1431
页数：1
相关论文
共 50 条
  • [31] The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis
    Wu, Yi-Ying
    Huang, Tzu-Chuan
    Tsai, Tsung-Neng
    Chen, Jia-Hong
    Dai, Ming-Shen
    Chang, Ping-Ying
    Ho, Ching-Liang
    Ye, Ren-Hua
    Chung, Tsai-Rong
    Chen, Yeu-Chin
    Chao, Tsu-Yi
    PLOS ONE, 2016, 11 (03):
  • [32] Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.
    Miles, David
    Lacasia, Andrea
    Lee, Luen
    Dana, Kenneth
    Heeson, Sarah
    Knott, Adam
    Portera, Chia C.
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
    Otoya, Iris
    Valdiviezo, Natalia
    Morante, Zaida
    Calle, Cindy
    Ferreyra, Yomali
    Huarcaya-Chombo, Norma
    Polo-Mendoza, Gabriela
    Castaneda, Carlos
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [34] SAFEHER: A STUDY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB (H-SC) AS ADJUVANT THERAPY IN PATIENTS WITH EARLY HER2-POSITIVE BREAST CANCER (EBC)
    Gligorov, J.
    Azim, H. A.
    Ataseven, B.
    Delaurentiis, M.
    Jung, K. H.
    Herbst, F.
    Llombart, A.
    Manikhas, A.
    Osborne, S.
    Pivot, X.
    ANNALS OF ONCOLOGY, 2012, 23 : 114 - 115
  • [35] FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
    Gao, Jennifer J.
    Osgood, Christy L.
    Gong, Yutao
    Zhang, Hui
    Bloomquist, Erik W.
    Jiang, Xiling
    Qiu, Junshan
    Yu, Jingyu
    Song, Pengfei
    Rahman, Nam Atiqur
    Chiu, Haw-Jyh
    Ricks, Tiffany K.
    Rizvi, Fatima
    Hou, Sherry
    Wilson, Willie
    Abukhdeir, Abde M.
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Pierce, William F.
    Bhatnagar, Vishal
    Kluetz, Paul G.
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2126 - 2129
  • [36] HOSPITAL CAPACITY TOOL TO ASSESS THE POTENTIAL IMPACT OF USING A FIXED DOSE COMBINATION OF PERTUZUMAB/TRASTUZUMAB FOR SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS PERTUZUMAB/ TRASTUZUMAB IN HER2+BREAST CANCER
    Cunha, A.
    VALUE IN HEALTH, 2023, 26 (12) : S296 - S296
  • [37] White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
    Christian Jackisch
    Federico Manevy
    Suzanne Frank
    Nicki Roberts
    Jason Shafrin
    Advances in Therapy, 2022, 39 : 833 - 844
  • [38] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
    Xu, Dongdong
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study
    ten Tije, A. J.
    van Steenis, S.
    Briers, J.
    Elsten, E. M. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S330 - S330
  • [40] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
12345